JP2020531084A - 栄養調合物の補給のためのデバイスおよび方法 - Google Patents
栄養調合物の補給のためのデバイスおよび方法 Download PDFInfo
- Publication number
- JP2020531084A JP2020531084A JP2020508404A JP2020508404A JP2020531084A JP 2020531084 A JP2020531084 A JP 2020531084A JP 2020508404 A JP2020508404 A JP 2020508404A JP 2020508404 A JP2020508404 A JP 2020508404A JP 2020531084 A JP2020531084 A JP 2020531084A
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- chamber
- container
- nutritional formulation
- lipids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 259
- 238000009472 formulation Methods 0.000 title claims description 255
- 235000016709 nutrition Nutrition 0.000 title claims description 222
- 238000000034 method Methods 0.000 title claims description 41
- 230000001502 supplementing effect Effects 0.000 title claims description 18
- 150000002632 lipids Chemical class 0.000 claims abstract description 313
- 108090001060 Lipase Proteins 0.000 claims abstract description 60
- 102000004882 Lipase Human genes 0.000 claims abstract description 60
- 239000004367 Lipase Substances 0.000 claims abstract description 58
- 235000019421 lipase Nutrition 0.000 claims abstract description 58
- 239000012530 fluid Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 description 58
- 235000020256 human milk Nutrition 0.000 description 29
- 210000004251 human milk Anatomy 0.000 description 23
- 239000003925 fat Substances 0.000 description 22
- 235000019197 fats Nutrition 0.000 description 21
- 239000002245 particle Substances 0.000 description 21
- 239000003623 enhancer Substances 0.000 description 16
- 239000008267 milk Substances 0.000 description 14
- 210000004080 milk Anatomy 0.000 description 14
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 12
- 235000013350 formula milk Nutrition 0.000 description 12
- 235000021588 free fatty acids Nutrition 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 12
- 235000013336 milk Nutrition 0.000 description 12
- 230000007062 hydrolysis Effects 0.000 description 11
- 238000006460 hydrolysis reaction Methods 0.000 description 11
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 10
- 239000013589 supplement Substances 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 9
- 230000037406 food intake Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 5
- 230000005484 gravity Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 208000011231 Crohn disease Diseases 0.000 description 4
- 102100040402 Phlorizin hydrolase Human genes 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000003833 bile salt Substances 0.000 description 4
- 108010087173 bile salt-stimulated lipase Proteins 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 150000004668 long chain fatty acids Chemical class 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 235000016236 parenteral nutrition Nutrition 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- 102100035687 Bile salt-activated lipase Human genes 0.000 description 3
- 206010016717 Fistula Diseases 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 229930003270 Vitamin B Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 229940093761 bile salts Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 235000021323 fish oil Nutrition 0.000 description 3
- 230000003890 fistula Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 235000021048 nutrient requirements Nutrition 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000033293 Jejunal fistula Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010025476 Malabsorption Diseases 0.000 description 2
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 235000019625 fat content Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 235000021049 nutrient content Nutrition 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019624 protein content Nutrition 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- -1 triglycerides Chemical class 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010056375 Bile duct obstruction Diseases 0.000 description 1
- 0 CCC(C)(CCC(CC=*=C)CC=I)N=N Chemical compound CCC(C)(CCC(CC=*=C)CC=I)N=N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 241000146387 Chromobacterium viscosum Species 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 208000029497 Elastoma Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 102400000471 Isomaltase Human genes 0.000 description 1
- 206010023648 Lactase deficiency Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010026867 Oligo-1,6-Glucosidase Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 101000966369 Rhizopus oryzae Lipase Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- 208000004622 abetalipoproteinemia Diseases 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000004204 exocrine pancreatic function Effects 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229940050549 fiber Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J9/00—Feeding-bottles in general
- A61J9/005—Non-rigid or collapsible feeding-bottles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2093—Containers having several compartments for products to be mixed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2089—Containers or vials which are to be joined to each other in order to mix their contents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J15/00—Feeding-tubes for therapeutic purposes
- A61J15/0003—Nasal or oral feeding-tubes, e.g. tube entering body through nose or mouth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J15/00—Feeding-tubes for therapeutic purposes
- A61J15/0026—Parts, details or accessories for feeding-tubes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
- A61J1/067—Flexible ampoules, the contents of which are expelled by squeezing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/0015—Devices specially adapted for taking medicines
- A61J7/0053—Syringes, pipettes or oral dispensers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Fluid Mechanics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Dairy Products (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Fats And Perfumes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
本願は、そのそれぞれの全体が、参照することによって本明細書に組み込まれる、2017年8月17日に出願された米国仮出願第62/546,817号の優先権の利益を主張する、2018年8月15日に出願された米国非仮出願第(係属中)号の優先権の利益を主張する。
本開示の実施形態は、栄養調合物を調製および/または補給するためのデバイスおよび方法を対象とし、より具体的には、栄養調合物に脂質源からの加水分解された脂質を補給するためのデバイスおよび方法を対象とする。
早産児は、多くの場合、未熟胃腸(GI)系を持って生まれる。その結果、早産児は、適切な栄養を受容するように、1つ以上の栄養調合物内に提供され得る、そのGI系が消化するための具体的形態の栄養素を要求し得る。早産児は、多くの場合、生後数時間以内に、非経口栄養(PN)を与えられる。PNを介した少量の栄養が、乳児のGI系に呼び水が差され始める間に投与され得る。乳児が、より大きい体積に耐え始めるにつれて、PNから離脱され、概して、例えば、母親自身の母乳(MoM)、ドナー母親の母乳(DM)、乳児用調合物(IF)、および/または付加的栄養強化剤を含む、1つ以上の栄養調合物から成る、経口または経腸給送に遷移され得る。排他的にMoMを使用することが好ましくあり得るが、しかしながら、母親は、最適成長および発達のために要求される1日のカロリーを提供するために、十分な母乳を供給不可能である場合がある。本欠陥を補うために、MoMは、例えば、収集、濾過、および/または熱低温殺菌され得る、DMを補給され得る。いくつかの事例では、乳児用調合物を使用することは、あまり好ましくない場合があるが、MoMおよびDMは、本質的に低カロリーであり得る。加えて、ヒト母乳バンクの数は、世界的に急増しつつあるが、あまり調整されておらず、それらが提供する母乳のカロリーおよび栄養素含有量は、著しく変動し得る。
本開示の例示的実施形態は、脂質源と、容器の出口に流動的に接続される、チャンバとを含有するように構成される、容器を有する、デバイスを対象とし得る。チャンバは、容器からチャンバの中に解放されると、それに沿って脂質が流動する、チャンバ内の流路内に位置付けられる、不動化されたリパーゼを含有してもよい。デバイスはまた、チャンバを通して通過後、それを通して脂質が流動する、出口を含んでもよい。
ここで、下記に説明され、付随の図面に図示される、本開示の例示的実施形態が、詳細に参照されるであろう。可能である場合は常に、同一参照番号が、同一または同様の部分を指すために図面全体を通して使用されるであろう。
Claims (23)
- デバイスであって、
脂質源を含有するように構成される容器と、
前記容器の出口に流動的に接続されるチャンバと、
不動化されたリパーゼであって、前記不動化されたリパーゼは、前記チャンバ内に含有され、前記チャンバ内の流路内に位置付けられ、前記容器から前記チャンバの中に解放されると、前記流路に沿って脂質が流動する、不動化されたリパーゼと、
出口であって、前記チャンバを通して通過後、前記出口を通して前記脂質が流動する、出口と
を備える、デバイス。 - 前記容器は、前記出口を除きシールされる、請求項1に記載のデバイス。
- 前記容器は、前記チャンバに除去可能に結合される、請求項1に記載のデバイス。
- 前記容器は、圧縮性である、請求項1に記載のデバイス。
- 前記出口に流動的に結合されるコネクタをさらに備え、前記コネクタは、
流体の流動を受容するための第1の開口部と、
前記流体の流動を出力するための第2の開口部と、
前記コネクタを通して前記第1の開口部から前記第2の開口部まで延在するコネクタ流路であって、前記コネクタ流路は、出力アセンブリに流動的に接続される、コネクタ流路と
を含む、請求項1に記載のデバイス。 - 前記コネクタと前記出口との間に位置するインターフェースをさらに備え、前記インターフェースを通して、前記脂質が、前記出口から前記コネクタの中に流動する、請求項5に記載のデバイス。
- 前記インターフェースは、前記コネクタに除去可能に接続される、請求項6に記載のデバイス。
- 前記容器内に含有される脂質源をさらに備える、請求項1に記載のデバイス。
- 前記脂質は、2つ以上の異なるタイプの脂質を含む、請求項8に記載のデバイス。
- デバイスであって、
容器と、
前記容器内に含有される脂質源と、
前記容器内の開口部に結合されるチャンバと、
前記チャンバに結合される出力アセンブリと、
前記容器内の開口部から、前記チャンバを通して、および前記出力アセンブリを通して延在する流路であって、前記容器から解放されると、前記流路に沿って脂質が前記デバイスを通して流動する、流路と、
前記チャンバ内に含有され、前記流路内に位置する不動化されたリパーゼであって、前記リパーゼは、前記脂質が前記チャンバを通して流動するにつれて、前記脂質を加水分解するように構成される、リパーゼと
を備える、デバイス。 - 前記容器は、1つのみの開口部を含む、請求項10に記載のデバイス。
- 前記容器は、圧縮性である、請求項10に記載のデバイス。
- 前記出力アセンブリは、第1の端部と、第2の端部とを有し、前記第1の端部は、前記チャンバに結合され、前記第1の端部は、前記第2の端部の幅を上回る幅を有する、請求項10に記載のデバイス。
- 前記出力アセンブリは、第1の端部と、第2の端部とを有し、前記第1の端部は、前記チャンバに結合され、前記第2の端部は、前記脂質が前記容器内に含有されるときにシールによって被覆され、前記脂質が前記流路に沿って流動するときに前記シールによって被覆されない開口部を有する、請求項10に記載のデバイス。
- 前記脂質は、2つ以上の異なるタイプの脂質を含む、請求項10に記載のデバイス。
- 栄養調合物に加水分解された脂質を補給する方法であって、前記方法は、
前記脂質をチャンバ内のリパーゼに暴露させることによって前記脂質を加水分解するために、デバイス内に貯蔵される脂質源を、不動化されたリパーゼを含有する前記デバイスのチャンバを通して通過させることと、
前記加水分解された脂質を前記デバイスのチャンバから出力することと、
前記加水分解された脂質を前記栄養調合物に添加することと
を含む、方法。 - 前記栄養調合物は、前記加水分解された脂質が前記栄養調合物に添加されるにつれて、前記デバイスを越えて流動される、請求項16に記載の方法。
- 前記脂質を前記チャンバを通して通過させることに先立って、前記脂質源を調製することをさらに含む、請求項16に記載の方法。
- 前記脂質源を調製することは、少なくとも2つの異なるタイプの脂質をともに混合することを含む、請求項18に記載の方法。
- 前記脂質源は、前記チャンバを通して通過されることに先立って、前記デバイスの容器内に貯蔵され、前記方法はさらに、前記脂質源を前記チャンバを通して通過させることに先立って、前記容器を前記デバイスに取り付けることを含む、請求項16に記載の方法。
- 前記脂質源を前記チャンバを通して通過させることに先立って、前記デバイスを給送システムに取り付けることをさらに含む、請求項16に記載の方法。
- 前記加水分解された脂質が前記栄養調合物に添加された後、前記栄養調合物を対象に給送することをさらに含む、請求項21に記載の方法。
- 前記加水分解された脂質を前記栄養調合物に添加することは、前記加水分解された脂質を前記デバイスから前記栄養調合物を含有する容器の中に出力することを含む、請求項16に記載の方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022165407A JP2022179761A (ja) | 2017-08-17 | 2022-10-14 | 栄養調合物の補給のためのデバイスおよび方法 |
JP2023131909A JP7510721B2 (ja) | 2017-08-17 | 2023-08-14 | 栄養調合物の補給のためのデバイスおよび方法 |
JP2023202677A JP2024009345A (ja) | 2017-08-17 | 2023-11-30 | 栄養調合物の補給のためのデバイスおよび方法 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762546817P | 2017-08-17 | 2017-08-17 | |
US62/546,817 | 2017-08-17 | ||
US15/998,410 US11045396B2 (en) | 2017-08-17 | 2018-08-15 | Devices and methods for the supplementation of a nutritional formula |
US15/998,410 | 2018-08-15 | ||
PCT/US2018/000209 WO2019035936A1 (en) | 2017-08-17 | 2018-08-16 | DEVICES AND METHODS FOR SUPPLEMENTING A NUTRITIONAL FORMULA |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022165407A Division JP2022179761A (ja) | 2017-08-17 | 2022-10-14 | 栄養調合物の補給のためのデバイスおよび方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020531084A true JP2020531084A (ja) | 2020-11-05 |
JP2020531084A5 JP2020531084A5 (ja) | 2021-09-02 |
JP7334976B2 JP7334976B2 (ja) | 2023-08-29 |
Family
ID=65360470
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020508404A Active JP7334976B2 (ja) | 2017-08-17 | 2018-08-16 | 栄養調合物の補給のためのデバイスおよび方法 |
JP2022165407A Withdrawn JP2022179761A (ja) | 2017-08-17 | 2022-10-14 | 栄養調合物の補給のためのデバイスおよび方法 |
JP2023131909A Active JP7510721B2 (ja) | 2017-08-17 | 2023-08-14 | 栄養調合物の補給のためのデバイスおよび方法 |
JP2023202677A Pending JP2024009345A (ja) | 2017-08-17 | 2023-11-30 | 栄養調合物の補給のためのデバイスおよび方法 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022165407A Withdrawn JP2022179761A (ja) | 2017-08-17 | 2022-10-14 | 栄養調合物の補給のためのデバイスおよび方法 |
JP2023131909A Active JP7510721B2 (ja) | 2017-08-17 | 2023-08-14 | 栄養調合物の補給のためのデバイスおよび方法 |
JP2023202677A Pending JP2024009345A (ja) | 2017-08-17 | 2023-11-30 | 栄養調合物の補給のためのデバイスおよび方法 |
Country Status (12)
Country | Link |
---|---|
US (2) | US11045396B2 (ja) |
EP (1) | EP3668476A1 (ja) |
JP (4) | JP7334976B2 (ja) |
KR (2) | KR20240015739A (ja) |
CN (2) | CN111201006A (ja) |
AU (2) | AU2018316476B9 (ja) |
BR (1) | BR112020002976B1 (ja) |
CA (1) | CA3073007A1 (ja) |
IL (2) | IL311882A (ja) |
MX (1) | MX2020001729A (ja) |
WO (1) | WO2019035936A1 (ja) |
ZA (2) | ZA202000963B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022179761A (ja) * | 2017-08-17 | 2022-12-02 | アルクレスタ セラピューティクス, インコーポレイテッド | 栄養調合物の補給のためのデバイスおよび方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102186932B1 (ko) | 2012-02-17 | 2020-12-07 | 알크레스타, 인크. | 식이 지방산 수요를 공급하기 위한 방법들, 조성물들 및 디바이스들 |
US12048830B2 (en) | 2019-03-07 | 2024-07-30 | Kpr U.S., Llc | Delivery of fluid from a syringe |
CN111759144B (zh) * | 2020-07-14 | 2021-10-26 | 张家港江苏科技大学产业技术研究院 | 一种用于辅助老人自主进流食的杯子 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015513532A (ja) * | 2012-02-17 | 2015-05-14 | アルクレスタ, インコーポレイテッド | 食餌性脂肪酸の要求を満たすための方法、組成物、及び装置 |
WO2016120318A1 (en) * | 2015-01-30 | 2016-08-04 | Pronova Biopharma Norge As | Enteral feeding device |
US20170105903A1 (en) * | 2015-10-14 | 2017-04-20 | Alcresta Therapeutics, Inc. | Enteral feeding device and related methods of use |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2807384A (en) * | 1956-03-12 | 1957-09-24 | Lipari Michael | Compartmental dispensing receptacle |
US3838784A (en) * | 1973-04-12 | 1974-10-01 | Mead Johnson & Co | Diet feeding container |
JPS54132291A (en) | 1978-04-03 | 1979-10-15 | Kuraray Co Ltd | Novel bioreactor |
DE2935546C2 (de) | 1979-09-03 | 1983-05-11 | Lepharm- Pharmazeutische Entwicklungs- und Vertriebsgesellschaft mbH, 5000 Köln | Diätetische Lebensmittel mit Monoglyceriden von Fettsäuren |
JPS6027380A (ja) | 1983-07-25 | 1985-02-12 | Nitto Electric Ind Co Ltd | 酵素反応装置 |
US4637934A (en) * | 1984-04-12 | 1987-01-20 | Baxter Travenol Laboratories, Inc. | Liquid container with integral opening apparatus |
US4629742A (en) | 1986-01-27 | 1986-12-16 | Akzo America Inc. | Hydrolysis of fats |
JPH0198494A (ja) | 1987-10-09 | 1989-04-17 | Agency Of Ind Science & Technol | バイオリアクター |
US4944944A (en) | 1987-11-19 | 1990-07-31 | Oklahoma Medical Research Foundation | Dietary compositions and methods using bile salt-activated lipase |
JP2581749B2 (ja) | 1988-04-27 | 1997-02-12 | 株式会社資生堂 | 固定化酵素を用いた油脂の分解槽およびこの分解槽を用いた油脂の分解装置並びに油脂の分解方法 |
EP0671166B1 (en) * | 1991-04-26 | 2004-10-13 | Mitsubishi Pharma Corporation | Nutrient-supplying infusion |
US5902617A (en) | 1992-05-19 | 1999-05-11 | Pabst; Patrea L. | Enzyme supplemented baby formula |
US5259587A (en) * | 1992-06-08 | 1993-11-09 | Whitman Medical Corporation | Roller clamp |
US5362442A (en) | 1993-07-22 | 1994-11-08 | 2920913 Canada Inc. | Method for sterilizing products with gamma radiation |
US5531681A (en) | 1995-01-13 | 1996-07-02 | Abbott Laboratories | Apparatus for altering composition of nutritional product during enteral tube feeding |
US5707353A (en) | 1995-12-21 | 1998-01-13 | Abbott Laboratories | Oral administration of beneficial agents |
US6541606B2 (en) | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
US6749851B2 (en) | 2001-08-31 | 2004-06-15 | Clearant, Inc. | Methods for sterilizing preparations of digestive enzymes |
US7410663B2 (en) | 2002-08-07 | 2008-08-12 | Kao Corporation | Oil or fat composition |
US20040209953A1 (en) | 2002-12-06 | 2004-10-21 | Wai Lee Theresa Siu-Ling | Glyceride compositions and methods of making and using same |
JP2004248671A (ja) | 2003-01-31 | 2004-09-09 | Rinoru Oil Mills Co Ltd | 共役リノール酸異性体の精製方法およびその用途 |
CA2551882A1 (en) | 2004-01-19 | 2005-08-11 | Martek Biosciences Corporation | Reelin deficiency or dysfunction and methods related thereto |
WO2005084129A2 (en) | 2004-03-04 | 2005-09-15 | Htl High-Tech Lipids Ltd. | Structured triglycerides and emulsions comprising same |
JP2005272307A (ja) | 2004-03-23 | 2005-10-06 | Dd Planning Kk | 抗菌・防カビ・消臭剤の噴霧方法及びその噴霧装置 |
SE0401145D0 (sv) | 2004-04-30 | 2004-04-30 | Mats Malmqvist | Continuous flow reaction vessel system |
MX2007004534A (es) | 2004-10-14 | 2007-11-08 | Altus Pharmaceuticals Inc | Composiciones que contienen lipasa, proteasa y amilasa para tratar la insuficiencia pancreatica. |
GB0504333D0 (en) | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Treatment of cytokine dysregulation |
US7582474B2 (en) | 2005-07-11 | 2009-09-01 | Honeywell International Inc. | Process reactor with layered packed bed |
WO2008054192A1 (en) | 2006-11-02 | 2008-05-08 | N.V. Nutricia | Use of nutritional compositions for preventing disorders |
WO2007120719A2 (en) * | 2006-04-10 | 2007-10-25 | Medical Instill Technologies, Inc. | Ready to drink container with nipple and needle penetrable and laser resealable portion, and related method |
WO2008012233A2 (de) | 2006-07-26 | 2008-01-31 | Basf Se | Thermoplastische formmassen mit hoher steifigkeit |
TW200835474A (en) * | 2006-11-17 | 2008-09-01 | Novartis Ag | Integrated storage and delivery systems for nutritional compositions |
UA97127C2 (uk) | 2006-12-06 | 2012-01-10 | Бандж Ойлз, Инк. | Спосіб безперервної ферментативної обробки композиції, що містить ліпід, та система для його здійснення |
WO2008127567A1 (en) | 2007-04-13 | 2008-10-23 | Beth Israel Deaconess Medical Center, Inc. | Novel nutritional food products for improved digestion and intestinal absorption |
DE102007031689A1 (de) | 2007-07-06 | 2009-01-08 | Evonik Goldschmidt Gmbh | Enzympräparate |
EP2205497A4 (en) | 2007-09-06 | 2012-10-24 | Suremilk Llc | UNIVERSAL DRINKING ADAPTER FOR DRINKING BOTTLES FOR LIQUID CONSUMPTION AND DEVICES AND DEVICES FOR DETERMINING SMALL MOLECULES, METAL IONS, ENDOTOXINS AND BACTERIA IN MILK, AND METHODS OF USE THEREOF |
US8206772B2 (en) | 2007-11-08 | 2012-06-26 | Kraft Foods Global Brands Llc | Structured lipid compositions and methods of formulation thereof |
AU2009207823B2 (en) * | 2008-01-24 | 2015-02-19 | Société des Produits Nestlé S.A. | Capsule containing nutritional ingredients and method of delivery of a nutritional liquid from the capsule |
US20120279939A1 (en) | 2008-10-27 | 2012-11-08 | Lee Jeong-Min | Bottle cap |
FR2955459B1 (fr) | 2010-01-28 | 2013-11-22 | Polaris | Composition huileuse riche en monoglycerides de dha |
AR082943A1 (es) | 2010-08-06 | 2013-01-23 | Aptalis Pharma Ltd | Formula nutricional predigerida |
CA2821935A1 (en) | 2010-12-29 | 2012-07-05 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome in an infant, toddler, or child |
US9920294B2 (en) | 2013-02-15 | 2018-03-20 | Douglas T. Gjerde | Devices and methods for purification, detection and use of biological cells |
US20140378419A1 (en) * | 2013-06-21 | 2014-12-25 | Mead Johnson Nutrition Company | Compositions and Methods for Nutrient Delivery |
EP3030257B1 (en) | 2013-08-09 | 2020-02-19 | Allergan Pharmaceuticals International Limited | Digestive enzyme composition suitable for enteral administration |
EP3329899B1 (en) * | 2014-09-04 | 2019-11-06 | Corpak Medsystems, Inc. | Gastric systems, apparatus, and methods for use with enteral feeding |
US11045396B2 (en) * | 2017-08-17 | 2021-06-29 | Alcresta Therapeutics, Inc. | Devices and methods for the supplementation of a nutritional formula |
-
2018
- 2018-08-15 US US15/998,410 patent/US11045396B2/en active Active
- 2018-08-16 EP EP18779070.4A patent/EP3668476A1/en active Pending
- 2018-08-16 IL IL311882A patent/IL311882A/en unknown
- 2018-08-16 JP JP2020508404A patent/JP7334976B2/ja active Active
- 2018-08-16 CN CN201880062544.7A patent/CN111201006A/zh active Pending
- 2018-08-16 AU AU2018316476A patent/AU2018316476B9/en active Active
- 2018-08-16 KR KR1020247002819A patent/KR20240015739A/ko active Application Filing
- 2018-08-16 CA CA3073007A patent/CA3073007A1/en active Pending
- 2018-08-16 BR BR112020002976-9A patent/BR112020002976B1/pt active IP Right Grant
- 2018-08-16 CN CN202311438240.5A patent/CN117357400A/zh active Pending
- 2018-08-16 IL IL272579A patent/IL272579B2/en unknown
- 2018-08-16 KR KR1020207007311A patent/KR102630613B1/ko active IP Right Grant
- 2018-08-16 WO PCT/US2018/000209 patent/WO2019035936A1/en unknown
- 2018-08-16 MX MX2020001729A patent/MX2020001729A/es unknown
-
2020
- 2020-02-14 ZA ZA2020/00963A patent/ZA202000963B/en unknown
-
2021
- 2021-05-11 US US17/317,374 patent/US20210259924A1/en not_active Abandoned
-
2022
- 2022-01-17 ZA ZA2022/00773A patent/ZA202200773B/en unknown
- 2022-10-14 JP JP2022165407A patent/JP2022179761A/ja not_active Withdrawn
-
2023
- 2023-08-14 JP JP2023131909A patent/JP7510721B2/ja active Active
- 2023-11-30 JP JP2023202677A patent/JP2024009345A/ja active Pending
-
2024
- 2024-04-24 AU AU2024202663A patent/AU2024202663A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015513532A (ja) * | 2012-02-17 | 2015-05-14 | アルクレスタ, インコーポレイテッド | 食餌性脂肪酸の要求を満たすための方法、組成物、及び装置 |
WO2016120318A1 (en) * | 2015-01-30 | 2016-08-04 | Pronova Biopharma Norge As | Enteral feeding device |
US20170105903A1 (en) * | 2015-10-14 | 2017-04-20 | Alcresta Therapeutics, Inc. | Enteral feeding device and related methods of use |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022179761A (ja) * | 2017-08-17 | 2022-12-02 | アルクレスタ セラピューティクス, インコーポレイテッド | 栄養調合物の補給のためのデバイスおよび方法 |
JP7510721B2 (ja) | 2017-08-17 | 2024-07-04 | アルクレスタ セラピューティクス, インコーポレイテッド | 栄養調合物の補給のためのデバイスおよび方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20200051639A (ko) | 2020-05-13 |
IL272579B2 (en) | 2024-09-01 |
AU2018316476A1 (en) | 2020-02-27 |
ZA202200773B (en) | 2024-05-30 |
JP7510721B2 (ja) | 2024-07-04 |
AU2024202663A1 (en) | 2024-05-16 |
US20190053987A1 (en) | 2019-02-21 |
ZA202000963B (en) | 2023-01-25 |
IL272579B1 (en) | 2024-05-01 |
IL272579A (en) | 2020-03-31 |
JP2024009345A (ja) | 2024-01-19 |
KR102630613B1 (ko) | 2024-01-30 |
JP7334976B2 (ja) | 2023-08-29 |
US20210259924A1 (en) | 2021-08-26 |
JP2023156432A (ja) | 2023-10-24 |
AU2018316476B9 (en) | 2024-02-29 |
WO2019035936A1 (en) | 2019-02-21 |
EP3668476A1 (en) | 2020-06-24 |
IL311882A (en) | 2024-06-01 |
AU2018316476B2 (en) | 2024-02-15 |
MX2020001729A (es) | 2020-03-20 |
JP2022179761A (ja) | 2022-12-02 |
BR112020002976A2 (pt) | 2020-08-11 |
CA3073007A1 (en) | 2019-02-21 |
CN111201006A (zh) | 2020-05-26 |
BR112020002976B1 (pt) | 2023-10-31 |
US11045396B2 (en) | 2021-06-29 |
CN117357400A (zh) | 2024-01-09 |
KR20240015739A (ko) | 2024-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7510721B2 (ja) | 栄養調合物の補給のためのデバイスおよび方法 | |
JP2024023962A (ja) | 栄養調合物の調製のためのデバイスおよび方法 | |
EP3678496B1 (en) | Devices and methods for preparing and administering a nutritional formula |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210721 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210721 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220705 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221014 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230525 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230601 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230721 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230809 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7334976 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |